Literature DB >> 18220592

Molecular mechanisms of skeletal muscle insulin resistance in type 2 diabetes.

Karim Bouzakri1, Heikki A Koistinen, Juleen R Zierath.   

Abstract

Type 2 (non-insulin-dependent) diabetes mellitus afflicts millions of people worldwide and is one of the main causes of morbidity and mortality. Current therapeutic agents to treat Type 2 diabetes are insufficient and thus, newer approaches are desperately needed. Type 2 diabetes is manifested by progressive metabolic impairments in tissues such as skeletal muscle, adipose tissue and liver, such that these tissues become less responsive to insulin. Skeletal muscle is quantitatively the most important tissue involved in maintaining glucose homeostasis under insulin-stimulated conditions, and is a major site of insulin resistance in Type 2 diabetic patients. At the cellular level, glucose transport into skeletal muscle is the rate-limiting step for whole body glucose uptake and a primary site of insulin resistance in Type 2 diabetes. Thus, skeletal muscle is a key insulin target tissue that harbours intrinsic defects that impinges upon whole body glucose homeostasis. Here, we review the current knowledge of signalling events that regulate glucose transport in human skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 18220592     DOI: 10.2174/1573399054022785

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  36 in total

1.  Rab8A and Rab13 are activated by insulin and regulate GLUT4 translocation in muscle cells.

Authors:  Yi Sun; Philip J Bilan; Zhi Liu; Amira Klip
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

2.  Protein phosphatase 1 regulatory subunit 12A and catalytic subunit δ, new members in the phosphatidylinositide 3 kinase insulin-signaling pathway.

Authors:  Thangiah Geetha; Paul Langlais; Michael Caruso; Zhengping Yi
Journal:  J Endocrinol       Date:  2012-06-22       Impact factor: 4.286

3.  Transplantation of neuregulin 4-overexpressing adipose-derived mesenchymal stem cells ameliorates insulin resistance by attenuating hepatic steatosis.

Authors:  Wenyue Wang; Yuxiang Zhang; Chengcan Yang; Yanni Wang; Jiahui Shen; Meilong Shi; Bing Wang
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-01

Review 4.  Skeletal muscle inflammation and insulin resistance in obesity.

Authors:  Huaizhu Wu; Christie M Ballantyne
Journal:  J Clin Invest       Date:  2017-01-03       Impact factor: 14.808

5.  Phosphorylation of the insulin receptor by AMP-activated protein kinase (AMPK) promotes ligand-independent activation of the insulin signalling pathway in rodent muscle.

Authors:  I Chopra; H F Li; H Wang; K A Webster
Journal:  Diabetologia       Date:  2011-12-30       Impact factor: 10.122

6.  Electrical pulse stimulation induces differential responses in insulin action in myotubes from severely obese individuals.

Authors:  Sanghee Park; Kristen D Turner; Donghai Zheng; Jeffrey J Brault; Kai Zou; Alec B Chaves; Thomas S Nielsen; Charles J Tanner; Jonas T Treebak; Joseph A Houmard
Journal:  J Physiol       Date:  2018-12-02       Impact factor: 5.182

Review 7.  Lipotoxicity and cardiac dysfunction in mammals and Drosophila.

Authors:  Ryan Tyge Birse; Rolf Bodmer
Journal:  Crit Rev Biochem Mol Biol       Date:  2011-08-19       Impact factor: 8.250

8.  Metabolic rates associated with membrane fatty acids in mice selected for increased maximal metabolic rate.

Authors:  Bernard W M Wone; Edward R Donovan; John C Cushman; Jack P Hayes
Journal:  Comp Biochem Physiol A Mol Integr Physiol       Date:  2013-02-16       Impact factor: 2.320

Review 9.  Pathogenesis of insulin resistance in skeletal muscle.

Authors:  Muhammad A Abdul-Ghani; Ralph A DeFronzo
Journal:  J Biomed Biotechnol       Date:  2010-04-26

10.  Liraglutide ameliorates palmitate-induced insulin resistance through inhibiting the IRS-1 serine phosphorylation in mouse skeletal muscle cells.

Authors:  Z Li; Y Zhu; C Li; Y Tang; Z Jiang; M Yang; C-L Ni; D Li; L Chen; W Niu
Journal:  J Endocrinol Invest       Date:  2018-01-27       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.